April 22, 2014 / 6:25 PM / in 4 years

Valeant won't pay whatever it takes for Allergan: CEO

(Reuters) - Valeant Pharmaceuticals Inc won’t pay whatever it takes to acquire rival Allergan Inc, and it will not turn its bid into an all-cash deal, Valeant Chief Executive Michael Pearson said on Tuesday in New York.

Valeant and activist investor Bill Ackman made an unsolicited $47 billion bid to buy Botox maker Allergan as it seeks to become one of the world’s five biggest drug companies.

Reporting by Bill Berkrot in New York; Writing by Rod Nickel in Winnipeg, Manitoba; Editing by Meredith Mazzilli

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below